[Shenfu注射改善慢性心力衰竭,通过调节基于NLRP3/caspase-1通路的烧灭酶]
Xing-Yu Fan1, Xiao-Qian Liao1, Shu-Min Huang2
1College of Traditional Chinese Medicine,Hunan University of Chinese Medicine Changsha 410208,China.
概括
沈福注射通过抑制NLRP3/caspase-1通路,减少炎症和热,改善慢性心力衰竭 (CHF). 这种治疗增强了心脏功能,并减轻了老鼠心肌纤维化.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性心力衰竭 (CHF) 是一种复杂的疾病,通常与炎症和心肌细胞死亡有关.
- 类似NOD的受体热蛋白域关联蛋白3 (NLRP3) /caspase-1信号通路在炎症反应和热中发挥着关键作用.
- 了解CHF干预的分子机制对于开发有效的治疗方法至关重要.
研究的目的:
- 在慢性心力衰竭 (CHF) 的老鼠模型中研究神福注射的治疗机制.
- 确定NOD类受体热蛋白域相关蛋白3 (NLRP3) /caspase-1信号通路在Shenfu注射的干预中的作用.
- 评估神福注射对心脏功能,心肌纤维化和心脏衰竭中热的作用.
主要方法:
- 通过注射异二烯醇,建立了CHF的老鼠模型.
- 动物接受了Shenfu注射,MCC950 (NLRP3抑制剂) 或作为对照对待.
- 评估了心脏功能 (LVEF,LVFS),血清炎症标志物 (NT-proBNP,IL-1β,IL-18),心肌形态和蛋白质表达 (NLRP3通路).
主要成果:
- 沈福注射显著改善了心脏功能 (LVEF,LVFS) 并降低了CHF大鼠的NT-proBNP水平.
- 用神福注射治疗显著降低了NLRP3,ASC,caspase-1,GSDMD-N,IL-1β和IL-18的表达.
- 沈福注射减轻了心肌纤维化,并降低了心肌细胞亡的速度,这是TUNEL染色证明的.
结论:
- 沈福注射有效地改善慢性心力衰竭 (CHF) 的心脏功能.
- 治疗效果通过抑制NLRP3/caspase-1信号通路进行介导.
- 沈福注射可缓解心肌纤维化和热,为心脏不全提供潜在的治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341